TY - JOUR
T1 - Implications of recurrent ischemia after reperfusion therapy in acute myocardial infarction
T2 - A comparison of thrombolytic therapy and primary angioplasty
AU - Stone, Gregg W.
AU - Grines, Cindy L.
AU - Browne, Kevin F.
AU - Marco, Jean
AU - Rothbaum, Donald
AU - O'Keefe, James
AU - Hartzler, Geoffrey O.
AU - Overlie, Paul
AU - Donohue, Bryan
AU - Chelliah, Noah
AU - Timmis, Gerald C.
AU - Vlietstra, Ronald
AU - Puchrowicz-ochocki, Sylvia
AU - O'Neill, William W.
N1 - Funding Information:
From the Cardiovascular Institute, El Camino Hospital, Mountain View, California; *Division of Cardiology, William Beaumont Hospital, Royal Oak, Michigan; ~Lakeland Regional Medical Center, Lakeland, Florida; ;Cliniquc Pasteur, Toulouse, France; §St. Vincent Hospital, Indianapolis, Indiana; IMid-America Heart Institute, Kansas Ci)., Missouri; ¶St. Ma W of the Plains, Lubbock, Texas; #Allegheny General Hospital, Pittsburgh, Pennsylvania: and **United Hospital, Grand Forks, North Dakota. A complete list of collaborators and participating centers appears in reference 13. This study was funded by the participating institutions and investigators, with no industw support. Drs. Stone, Hartzler and O'Neill have served as consultants to the angioplas~, indust~'. Dr. Michael Vandormael, a participating investigator, owns stock in Genentech Corp., South San Francisco, California.
PY - 1995/7
Y1 - 1995/7
N2 - Objectives.: The purpose of this study was to examine the incidence and implications of recurrent ischemia after different reperfusion strategies in acute myocardial infarction. Background.: The rates and effects of recurrent ischemia after reperfusion with thrombolytic therapy and with primary percutaneous transluminal coronary angioplasty have not been compared. Methods.: At 12 centers 395 patients presenting within 12 h of the onset of acute myocardial infarction were prospectively randomized to receive recombinant tissue-type plasminogen activator (rt-PA) or primary coronary angioplasty. Sixteen clinical variables were examined by using univariate and multiple logistic regression analysis to identify the predictors of recurrent ischemia. The relation of recurrent ischemic events to patient outcome was analyzed. Results.: Recurrent ischemia developed in 76 patients (19.2%) before hospital discharge, resulting in reinfarction in 18 patients (4.6%) and death in 5 (2.6%). Recurrent ischemia occurred in 56 patients (28.0%) after rt-PA but in only 20 patients (10.3%) after coronary angioplasty (p < 0.0001), directly contributing to a higher rate of death or reinfarction (7.5% vs. 3.1%, p = 0.05), catheterization and revascularization procedures and prolonged hospital stay after thrombolysis. By multivariate analysis, treatment with coronary angioplasty rather than rt-PA was the strongest predictor of freedom from recurrent ischemia. Although the incidence of recurrent ischemia after angioplasty and after rt-PA was similar within the 1st 2 days of admission (9.2% vs. 14.5%, p = 0.11), after hospital day 2 recurrent ischemia occurred in only 2 patients who received primary angioplasty compared with 27 patients who received rt-PA (1.1% vs. 13.5%, p < 0.0001). Conclusions.: The development of recurrent ischemia adversely affects patient outcome, increasing morbidity, mortality and resource utilization. The much lower rate of recurrent ischemia after primary coronary angioplasty than after rt-PA results in improved survival without reinfarction and allows a shorter, less complicated hospital stay. Given the extremely low rate of recurrent ischemia after hospital day 2, safe early discharge on day 3 after primary coronary angioplasty should be feasible in selected patients with acute myocardial infarction.
AB - Objectives.: The purpose of this study was to examine the incidence and implications of recurrent ischemia after different reperfusion strategies in acute myocardial infarction. Background.: The rates and effects of recurrent ischemia after reperfusion with thrombolytic therapy and with primary percutaneous transluminal coronary angioplasty have not been compared. Methods.: At 12 centers 395 patients presenting within 12 h of the onset of acute myocardial infarction were prospectively randomized to receive recombinant tissue-type plasminogen activator (rt-PA) or primary coronary angioplasty. Sixteen clinical variables were examined by using univariate and multiple logistic regression analysis to identify the predictors of recurrent ischemia. The relation of recurrent ischemic events to patient outcome was analyzed. Results.: Recurrent ischemia developed in 76 patients (19.2%) before hospital discharge, resulting in reinfarction in 18 patients (4.6%) and death in 5 (2.6%). Recurrent ischemia occurred in 56 patients (28.0%) after rt-PA but in only 20 patients (10.3%) after coronary angioplasty (p < 0.0001), directly contributing to a higher rate of death or reinfarction (7.5% vs. 3.1%, p = 0.05), catheterization and revascularization procedures and prolonged hospital stay after thrombolysis. By multivariate analysis, treatment with coronary angioplasty rather than rt-PA was the strongest predictor of freedom from recurrent ischemia. Although the incidence of recurrent ischemia after angioplasty and after rt-PA was similar within the 1st 2 days of admission (9.2% vs. 14.5%, p = 0.11), after hospital day 2 recurrent ischemia occurred in only 2 patients who received primary angioplasty compared with 27 patients who received rt-PA (1.1% vs. 13.5%, p < 0.0001). Conclusions.: The development of recurrent ischemia adversely affects patient outcome, increasing morbidity, mortality and resource utilization. The much lower rate of recurrent ischemia after primary coronary angioplasty than after rt-PA results in improved survival without reinfarction and allows a shorter, less complicated hospital stay. Given the extremely low rate of recurrent ischemia after hospital day 2, safe early discharge on day 3 after primary coronary angioplasty should be feasible in selected patients with acute myocardial infarction.
UR - http://www.scopus.com/inward/record.url?scp=0029001918&partnerID=8YFLogxK
U2 - 10.1016/0735-1097(95)00138-P
DO - 10.1016/0735-1097(95)00138-P
M3 - Article
C2 - 7797777
AN - SCOPUS:0029001918
SN - 0735-1097
VL - 26
SP - 66
EP - 72
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 1
ER -